Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases
Wednesday, September 17, 2014
TOKYO, JAPAN (September 16, 2014)—The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases—malaria, dengue and Chagas disease. The announcement marks the GHIT Fund’s third round of grant investments since November 2013—totaling $33.5 million—aimed at diseases that sicken and kill the world’s poorest of the poor.
“Still breathless from global efforts at elimination, today the world confronts a disturbing reemergence of infectious disease that knows no borders. In response and recognition, today we announce a total portfolio of 29 partnerships representing over $33 million in investments. This portfolio is a testament to our commitment to investing in the health of the more than 4 billion people who battle daily against infectious diseases,” said Dr. BT Slingsby, CEO of the GHIT Fund.